Oxbridge Re Limited (OXBRW)
NASDAQ: OXBRW
· Real-Time Price · USD
0.46
0.02 (4.57%)
At close: Jun 02, 2025, 2:58 PM
Oxbridge Re Revenue Breakdown
| Period Ending | Dec 31, 2022 | Dec 31, 2014 |
|---|---|---|
| Property, Liability and Casualty Insurance Product Line Revenue | 995K | 4.82M |
| Property, Liability and Casualty Insurance Product Line Revenue Growth | -79.35% | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 505K | 431K | 432K | 566K | 488K | 475K | 628K | 677K | 403K | 363K | 323K | 389K | 338K | 460K | 280K | 312K | 252K | 262K | 239K | 282K | 246K | 259K | 264K | 280K | 264K | 301K | 305K | 367K | 318K | 231K | 370K | 390K | 335K | 333K | 346K | 377K | 364K | 411K | 353K | 321K | 350K |
| Selling, General, and Administrative Revenue Growth | +17.17% | -0.23% | -23.67% | +15.98% | +2.74% | -24.36% | -7.24% | +67.99% | +11.02% | +12.38% | -16.97% | +15.09% | -26.52% | +64.29% | -10.26% | +23.81% | -3.82% | +9.62% | -15.25% | +14.63% | -5.02% | -1.89% | -5.71% | +6.06% | -12.29% | -1.31% | -16.89% | +15.41% | +37.66% | -37.57% | -5.13% | +16.42% | +0.60% | -3.76% | -8.22% | +3.57% | -11.44% | +16.43% | +9.97% | -8.29% | n/a |
| Research and Development Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Research and Development Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |